ClinicalTrials.gg
RecruitingNCT06503068Updated Aug 16, 2024

Impact of NAFLD vs MAFLD Stigma on Quality of Life in Egyptian Patients

An observational study in NAFLD, sponsored by Tanta University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-16.

Sponsored by Tanta University · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Nov 2024, 1 year 11 months ago, but the record still lists the study as recruiting.
  • Started May 2024; still recruiting 2 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Ecologic or community
Time perspective
Cross-sectional
Enrollment
500
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Non-alcoholic Fatty Liver Disease by Tanta University — 6 open to participants now, 8 under way, 4 of them phase 3. Non-alcoholic Fatty Liver Disease · Tanta University.

Started
2024
the only one that year
Observational
Only one
of the 13
Registered
9th of 13
by date

Among the 13 studies in Non-alcoholic Fatty Liver Disease by Tanta University, this one is the only one that started in 2024, is the only observational one, and was the 9th registered.

Non-alcoholic Fatty Liver Disease

1,618 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

6 of the 13 studies in Non-alcoholic Fatty Liver Disease by Tanta University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Non-alcoholic Fatty Liver Disease by Tanta University, or all of them as a file.
02

Study summary

Non-alcoholic fatty liver disease (NAFLD) has become the leading cause of liver disease worldwide. The global burden of NAFLD is about 30% of the population, With a higher prevalence in Egypt about 47.5 %. The prevalence increases significantly with the presence of type 2 diabetes and obesity.

NAFLD is commonly associated with metabolic dysfunction and the development of cardiovascular disease. However, the NAFLD definition excludes other causes. It is not correlated with metabolic dysfunction and cardiovascular risk, so in 2020, the term metabolic-dysfunction-associated fatty liver disease (MAFLD) was suggested to replace the term NAFLD.

The nomenclature change was partly related to the stigma associated with the term NAFLD. As the words "alcoholic" and "fatty" were considered stigmatizing. A recent global survey showed that 26% of patients (57% in the USA and 7% in MENA) felt stigmatized relating to overweight/obesity and 8% of patients (22 % in the USA and 3% in MENA) felt stigmatized by the term NAFLD. While 34% and 38% of physicians considered the words "non-alcoholic" and "fatty" stigmatizing, respectively.

There is a discrepancy between the different regions of the world and between patients and providers regarding the perception of NAFLD/ MAFLD stigma. This study aims to assess the perception and stigmatization of various diagnostic terms (fatty liver, NAFLD \& MAFLD) among Egyptian patients and physicians. Also, to assess the impact of stigma on the quality of life and the motivations and barriers for lifestyle modification which is the cornerstone of NAFLD/MAFLD management.

Read the detailed description

This cross-sectional study will be carried out in collaboration between the Tropical Medicine Department and Public Health Department, Tanta University Hospitals. A questionnaire in both digital and written forms targeting patients with NAFLD/NASH and physicians treating NAFLD/NASH patients in Egypt.

Type of study:

Prospective, cross-sectional survey.

Duration of study:

Study will be carried out from May 2024 to August 2024 or until the target number is reached (about 500 subjects).

Target subjects:

The questionnaire will target a convenience sample of NAFLD/NASH patients and physicians treating NAFLD/NASH patients (about 500 subjects).

The questionnaire will be written and digital in both Arabic and English versions.

Methodology:

After designing the questionnaire, it will be discussed with other experts in the field, validity and reliability will be assessed and a pilot study will be done.

After an informed consent subject will answer a designed questionnaire either written or digital. 2 phases will be done The questionnaire will be divided into 3 sectors Sector 1: Demographic data: questions about [age, sex, residence, educational level, occupation (subspecialty), workplace] for all participants.

Sector 2: Socioeconomic level determination mainly for population :( Socio-economic data will be gathered through questions asking about the number of family members, number of rooms in the apartment, level of education, occupation, and cost per month).

Sector 3: the main work includes questions for patients: (patient awareness of NAFLD before diagnosis, presence and severity of liver fibrosis, presence of comorbidities, the diagnostic term they use to describe their disease, have they disclosed their condition to family or friends, have they experienced stigmatization or discriminations due to their disease and how frequently, how they feel about the words fatty, alcoholic, and metabolic, have they avoided or missed a visit with their physician due to NAFLD, patients concerns about the disease and its progression, barriers, and motivations for lifestyle modifications).

For physicians :(their clinical experience in NAFLD and the number of NAFLD/NASH patients they see per month, what terms they think are considered stigmatizing to their patients "fatty, non-alcoholic, overweight/obese, metabolic associated", does their patients feel discrimination due to their disease, would the name change help their patients, causes of frustration and discomfort when treating NAFLD patients, their opinion of what are the barriers and motivations for lifestyle modifications in their patients)

Ethical considerations:

A written or digital informed consent form authorizing the collection of this data was signed by all subjects The study will be approved by the Ethical Committee of Faculty of Medicine Tanta University.

The risks to the participants and measures needed to minimize these risks:

  • The privacy of the data of the patients will be maintained.
  • Any unexpected risks appear during the course of research will be cleared to the subjects and the ethical committee on time

Adequate provisions to maintain the privacy of participants and confidentially of data are as follows:

  • A code number for each patient will be used, and symbols for the name and address will be kept in a special file.
  • The investigators will hide the patients' names when the research is used
  • The investigators will use the results of the research only for scientific aims and not use it in other aims.

The endpoint of this study:

Assess the prevalence of NAFLD/MAFLD stigma among both patients and physicians, and the beneficence of name change from NAFLD to MAFLD in Egypt to determine the factors leading to lifestyle modifications in NAFLD/MAFLD patients, thus improving patients' quality of life.

03

Conditions studied

  • NAFLD

Keywords

  • Metabolic- associated fatty liver disease (MAFLD)
  • Non-alcoholic fatty liver disease (NAFLD)
  • stigma
  • Metabolic dysfunction-associated steatotic liver disease (MASLD)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

The questionnaire will target a convenience sample of NAFLD/NASH patients presenting to the Tropical Medicine Department clinics.

physicians treating NAFLD/NASH patients in Egypt

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients ≥ 18 years old diagnosed with NAFLD/ NASH and willing to complete the survey.
  • Physicians treating patients with NAFLD/NASH (hepatologists, gastroenterologists, endocrinologists, and internal medicine physicians).

Exclusion criteria

Exclusion Criteria:

  • Unwilling to participate
05

Study design

Observational model
Ecologic or community
Time perspective
Cross-sectional
Enrollment
500 participants (estimated)
Patient registry
No

Groups and cohorts

  • NAFLD/NASH patients

    Patients ≥ 18 years old diagnosed with NAFLD/ NASH and willing to complete the survey.

    Other: Questionnaire

  • Physicians

    Physicians treating patients with NAFLD/NASH (hepatologists, gastroenterologists, endocrinologists, and internal medicine physicians).

    Other: Questionnaire

Interventions

  • OtherQuestionnaire

    A questionnaire in both digital and written forms in both Arabic and English versions.

06

What researchers measure

Primary outcomes

  1. Awareness of NAFLD/MAFLD stigma in Egypt

    Using a questionnaire to assess awareness of stigma related to various diagnostic terms such as "fatty liver", "NAFLD", "MAFLD", and Metabolic dysfunction-associated steatotic liver disease "MASLD" in patients and in NAFLD/NASH treating physicians in Egypt.

    Time frame: till August 2024

  2. Perception of NAFLD/MAFLD stigma in Egypt

    Using a questionnaire to assess perception of stigma related to various diagnostic terms such as "fatty liver", "NAFLD", "MAFLD", and "MASLD" in patients and in NAFLD/NASH treating physicians in Egypt.

    Time frame: till August 2024

Secondary outcomes

  1. impact on quality of life

    Using a questionnaire to understand the impact of NAFLD vs MAFLD stigma on the quality of life in Egyptian patients

    Time frame: till August 2024

  2. Motivations to lifestyle changes

    Using a questionnaire to evaluate the motivation for lifestyle changes in Egyptian patients

    Time frame: till August 2024

  3. Barriers to lifestyle changes

    Using a questionnaire to evaluate the barriers for lifestyle changes in Egyptian patients

    Time frame: till August 2024

07

Study locations

1 of 1 sites recruiting
  • Tropical medicine department, Tanta University Hospitals
    Tanta, Gharbyea 31527, Egypt
    Recruiting
    • Ferial Elkalla, MD · Contactf.elkalla@gmail.com · 00201006023289
    • Shimaa M Ebrahim, MD · Sub investigator
    • Asmaa A Elfeky, MD · Sub investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2024 (actual). Primary completion is estimated for Nov 2024, 6 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2024
First posted
Jul 16, 2024
StartActual
May 1, 2024
Primary completionEst.
Nov 30, 2024
CompletionEst.
Dec 15, 2024
Last update
Aug 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06503068
Lead sponsor
Tanta University
Responsible party
Rania Mamdouh Elkafoury (Principle Investigator, Tanta University) — Principal investigator
First posted
Jul 16, 2024
Start date
May 1, 2024
Primary completion
Nov 30, 2024 (estimated)
Completion
Dec 15, 2024 (estimated)
Last update
Aug 16, 2024

Study contacts

Rania M Elkafoury, MD
Contact
rania.elkafoury@med.tanta.edu.eg
00201004672358
Shimaa M Ebrahim, MD
Contact
shimaaebrahim@med.tanta.edu.eg
00201020018360

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion